| Literature DB >> 30623268 |
Christina Kaijser Alin1, Elin Uzunel2, Ann-Charlotte Grahn Kronhed3,4, Hassan Alinaghizadeh2,5, Helena Salminen2,5.
Abstract
The treatment effect of an activating spinal orthosis on back pain and back extensor strength was compared to a training group and to a control group. Between the groups, there was no significant difference in back pain, back extensor strength, or kyphosis index after the 6 months of treatment.Entities:
Keywords: Back extensor muscle strength; Back pain; Kyphosis; Osteoporosis; Spinal orthosis; Vertebral fracture
Mesh:
Year: 2019 PMID: 30623268 PMCID: PMC6325994 DOI: 10.1007/s11657-018-0555-0
Source DB: PubMed Journal: Arch Osteoporos Impact factor: 2.617
Fig. 1Flow chart of the participants in the RCT
Changes in back pain and back extensor strength between groups at baseline and at follow-ups after 3 and 6 months analyzed according to intention to treat and by mixed linear model, showing the group vs time interaction LS mean ± SE, p value, effect size and power of test, adjusted for age, vertebral fractures, FVC, and examiner
| Treatment group | Baseline mean ± SEb | 3 months mean ± SEb | 6 months mean ± SEb | ES ( | Powerc | |||
|---|---|---|---|---|---|---|---|---|
| Back pain present VAS (mm) | Spinal orthosis | 35 | 23.60 ± 4.07 | 20.00 ± 3.83 | 24.95 ± 3.93 | < 0.01 | 0.08 | 0.92 |
| Training | 37 | 14.24 ± 3.81 | 14.09 ± 3.71 | 18.69 ± 3.76 | ||||
| Control | 35 | 24.87 ± 4.14 | 27–65 ± 3.72 | 21.55 ± 3.69 | ||||
| Back pain present Borg CR-10 | Spinal orthosis | 35 | 2.16 ± 0.29 | 1.96 ± 0.30 | 1.78 ± 0.30 | < 0.01 | 0.08 | 0.96 |
| Training | 37 | 1.73 ± 0.27 | 1.36 ± 0.29 | 1.38 ± 0.28 | ||||
| Control | 35 | 2.34 ± 0.28 | 2.36 ± 0.29 | 1.92 ± 0.28 | ||||
| Muscle strength (N) | Spinal orthosis | 35 | 65.89 ± 5.01 | 73.16 ± 5.15 | 82.48 ± 5.29 | < 0.01 | 0.09 | 0.99 |
| Training | 38 | 60.66 ± 4.82 | 67.32 ± 5.01 | 74.86 ± 5.04 | ||||
| Control | 36 | 58.93 ± 4.99 | 61.70 ± 5.12 | 65.41 ± 5.09 |
p value = interaction between time and treatment group
aEffect size (f2) is based on Cohen’s (1988) guidelines; f2 ≥ 0.02, f2 ≥ 0.15, and f2 ≥ 0.35 represent small, medium, and large effect size, respectively
bEstimated least square mean adjusted for age, vertebral fractures, and FVC and examiner
cPower of test showed that sample size was large enough to show a significant difference between the groups. Nevertheless, the contrast tests between the groups as a post hoc analysis showed no significant treatment effect
Fig. 2Box-plots of back extensor strength (mean, Newton) separated into study groups and study time
Baseline characteristics
| Spinal orthosis | Training | Control | ||
|---|---|---|---|---|
| Variable | Mean (SD) | Mean (SD) | Mean (SD) | |
| Present height (cm) | 159.8 (7.6) | 159.3 (7.6) | 161.5 (6.9) | 0.407 |
| Height young (cm) | 166.2 (5.7) | 165.6 (6.3) | 167.6 (5.7) | 0.303 |
| Weight (kg) | 64.7 (13.4) | 60.3 (8.5) | 66.1 (11.6) | 0.073 |
| Back muscle extensor strengtha (N) | 64.4 (32.8) | 59.6 (30.8) | 62.3 (25.2) | 0.791 |
| FVCb (l) | 2.7 (0.7) | 2.6 (0.7) | 2.7 (0.6) | 0.727 |
| Variable | Median (IQR) | Median (IQR) | Median (IQR) | |
| Age | 77.9 (68.0–83.4) | 77.6 (67.3–84.1) | 72.8 (67.5–78.2) | 0.201 |
| Visual Analogue Scale VAS back pain, recent (mm) | 22 (10–40) | 9 (1–30) | 21 (10–45) | 0.088 |
| Visual Analogue Scale VAS back pain, last week (mm) | 50 (28–69) | 39 (20–52) | 43 (20–61) | 0.181 |
| Borg CR-10 back pain, recent | 3 (1–3) | 2 (0.5–3) | 2 (1–3) | 0.049 |
| Borg CR-10 back pain, last week | 4 (2–7) | 3 (2–4) | 3 (3–5) | 0.168 |
| Variable | % | % | % | |
| Kyphotic index ≥ 13 | 51.4 | 50.0 | 56.8 | 0.826 |
| Bone-specific drugs | 44.7 | 47.4 | 51.4 | 0.847 |
| Calcium-vitamin D | 89.5 | 86.8 | 89.2 | 0.925 |
| Only vitamin D | 2.6 | 5.3 | 2.7 | 0.784 |
| Hip fracture self-reported | 5.3 | 10.5 | 8.1 | 0.704 |
| Wrist fracture self-reported | 26.3 | 23.7 | 27.0 | 0.942 |
| Vertebral fracture self-reported | 36.8 | 31.6 | 24.3 | 0.508 |
| Vertebral fracture X-ray | 47.1 | 46.0 | 38.2 | 0.725 |
aSpinomed n = 35, training n = 38, control n = 36
bFVC forced vital capacity
cOne-way ANOVA was used for comparisons of differences between the three treatment groups
dχ2 test for variables that were categories in proportions
The change in percentage of back extensor strength in each group, analyzed by paired t test. Analyses per protocol
| Baseline | 6 months | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment group | mean ± SD | 95% CI | mean ± SD | 95% CI | Change % | ||||
| Muscle strength (N) | Spinal orthosis | 25 | 64.4 ± 32.8 | 53.2–75.7 | 25 | 81.7 ± 41.3 | 65.4–98.0 | 26.9 | 0.053 |
| Training | 30 | 59.6 ± 30.8 | 49.5–69.8 | 30 | 72.8 ± 37.3 | 58.9–86.8 | 22.1 | 0.013 | |
| Control | 31 | 62.3 ± 25.2 | 53.7–70.8 | 31 | 68.4 ± 27.0 | 58.7–78.1 | 9.9 | 0.153 | |